First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors

Bendell, J; LoRusso, P; Overman, M; Noonan, AM; Kim, DW; Strickler, JH; Kim, SW; Clarke, S; George, TJ; Grimison, PS; Barve, M; Amin, M; Desai, J; Wise-Draper, T; Eck, S; Jiang, Y; Khan, AA; Wu, YL; Martin, P; Cooper, ZA; Elgeioushi, N; Mueller, N; Kumar, R; Patel, SP

Bendell, J (通讯作者)，Sarah Cannon Res Inst, Nashville, TN 37203 USA.;Bendell, J (通讯作者)，F Hoffmann La Roche Ltd, Roche Innovat Ctr Basel, Basel, Switzerland.

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2023; 72 (7): 2443

Abstract

BackgroundCD73 upregulation in tumors leads to local immunosuppression. This phase I, first-in-human study evaluated oleclumab (MEDI9447), an anti-CD7......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索